This short video provides a visual explanation of the unique mechanism of action of Sonnet’s FHAB platform.
Sonnet’s deep knowledge of immune biology is complemented by our extensive drug discovery and development expertise.
Our Fully Human Albumin Binding (FHAB) technology is the foundation of a modular, plug-and-play drug development platform with several distinct advantages:
Human Serum Albumin (HSA) is naturally present in the bloodstream and is the predominant protein in blood plasma. Albumin accumulates at sites of inflammation, including tumors. Following administration, Sonnet’s FHAB-conjugated therapies bind to and “hitch-hike” on patients’ endogenous HSA for transport to the target tissues.
FHAB utilizes a fully human single chain antibody fragment (scFv) capable of delivering one or two active biologic compounds that are attached using flexible, fully human linker peptides.
FHAB leverages human serum albumin to extend therapeutic half-life (pK) and enhance tumor delivery without the need for concentrated, potentially toxic doses.
FHAB employs a linear, flexible rod construct that binds HSA non-permanently, for better tissue penetration.
Importantly, the Sonnet FHAB is fully human, with a human glycosylation profile and can be easily manufactured in Chinese Hamster Ovary (CHO) cells.
